Related Experiment Video
Updated: Dec 24, 2025

03:53
An Orthotopic Sciatic Nerve Xenograft for Neurofibromatosis Type 1 Neurofibromas
Published on: October 10, 2025
337
Abstract:
A new clinical trial suggests that the MEK inhibitor selumetinib induces partial responses in children with neurofibromatosis type 1 who have inoperable plexiform neurofibromas. The drug led to confirmed partial responses in 70% of patients; progression-free survival was 84% after 3 years.
More Related Videos
09:33Author Spotlight: Finding New Therapeutic Targets for Malignant Peripheral Nerve Sheath Tumor Through Genome-Scale shRNA Screens
Published on: August 25, 2023
1.5K
09:37Defining Gene Functions in Tumorigenesis by Ex vivo Ablation of Floxed Alleles in Malignant Peripheral Nerve Sheath Tumor Cells
Published on: August 25, 2021
2.1K